News | February 10, 2024
Biocon Biologics partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore
The company recently received CEP certificate approval for Losartan Potassium by EDQM
Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
The company intends to respond to the two minor observations within the stipulated time
The registered capital of the newly founded company is € 50 million
Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023
Microdosing has emerged as a key trend in the pharmaceutical and nutritional markets
Subscribe To Our Newsletter & Stay Updated
